Clinical trials: Chronic Migraine Headache
- Condition Chronic Migraine Headache
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Migraine
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment…
- Trial name
- NCT04530110
- Testing
- Fremanezumab
- Where
- 70 sites in United States, Canada and 7 more
- Volunteers
- 499 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Migraine Disorders
Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults
This study will evaluate the efficacy, safety and tolerability of prophylactic (preventative) treatment with BOTOX® (onabotulinumtoxinA) compared to topiramate in adults with chronic migraine.
- Trial name
- NCT02191579
- Testing
- onabotulinumtoxinA, Topiramate
- Where
- 32 sites in United States
- Volunteers
- 282 people
- Sponsor
- Allergan
Treatment for Prevention of Chronic Migraine
A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
To assess the long-term safety and efficacy of erenumab.
- Trial name
- NCT02174861
- Testing
- Erenumab
- Where
- 65 sites in United States, Canada and 8 more
- Volunteers
- 609 people
- Sponsor
- Amgen
Migraine Disorders
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX®) as prescribed by the physician for headache prophylaxis in adults with chronic migraine. All treatment decisions lie with the physician.
- Trial name
- NCT01686581
- Testing
- botulinum toxin Type A
- Where
- 77 sites in Germany, Italy and 5 more
- Volunteers
- 641 people
- Sponsor
- Allergan
Chronic Migraine, Episodic Migraine
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic (CM) or episodic migraine (EM).
- Trial name
- JPN ATO OLE (NCT04437433)
- Testing
- Atogepant 60 mg
- Where
- 24 sites in Japan
- Volunteers
- 186 people
- Sponsor
- AbbVie
Migraine
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine.
- Trial name
- OASIS(CM) (NCT03832998)
- Testing
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
- Where
- 101 sites in United States, Belgium and 11 more
- Volunteers
- 284 people
- Sponsor
- Amgen
Migraine
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM).
- Trial name
- NCT04464707
- Testing
- Fremanezumab
- Where
- 89 sites in United States, Canada and 7 more
- Volunteers
- 292 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine Disorders
Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
The primary objective of this study is to evaluate the safety and efficacy of occipital nerve stimulation (ONS) using the Boston Scientific Corporation (BSC) Precision™ System in the management of intractable chronic migraine…
- Trial name
- OPTIMISE (NCT01775735)
- Testing
- Occipital nerve stimulator
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boston Scientific Corporation
Migraine Disorders
BOTOX® Prophylaxis in Patients With Chronic Migraine
This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic…
- Trial name
- NCT01432379
- Testing
- botulinum toxin Type A
- Where
- 4 sites in Germany, Spain and 2 more
- Volunteers
- 1,168 people
- Sponsor
- Allergan
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.
- Trial name
- NCT01662492
- Testing
- Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2
- Where
- 22 sites in United States
- Volunteers
- 125 people
- Sponsor
- Allergan
Chronic Migraine
Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
The purpose of this multi-center, prospective, double-blind, randomized, sham-controlled pilot study is to study feasibility and collect preliminary clinical data related to the safety and clinical benefits of daily use of…
- Trial name
- NCT01667250
- Testing
- GammaCore Active Device
- Where
- 6 sites in United States
- Volunteers
- 59 people
- Sponsor
- ElectroCore INC
Intractable Chronic Migraine
Peripheral Nerve Stimulation Registry for Intractable Migraine Headache
The purpose of this study is to evaluate the long-term safety and performance of neurostimulation for the treatment of intractable chronic migraine as well as to detect infrequent complications or problems only apparent in…
- Trial name
- Relief (NCT02227758)
- Where
- 18 sites in Belgium, Germany and 4 more
- Volunteers
- 112 people
- Sponsor
- Abbott Medical Devices
Migraine
Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
The purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.
- Trial name
- DRAGON (NCT03867201)
- Testing
- Erenumab
- Where
- 63 sites in China, India and 7 more
- Volunteers
- 557 people
- Sponsor
- Novartis Pharmaceuticals
Migraine Headache
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
This study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and…
- Trial name
- NCT03557333
- Testing
- INP104
- Where
- 36 sites in United States
- Volunteers
- 360 people
- Sponsor
- Impel Pharmaceuticals
Migraine
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
A migraine is a moderate to severe headache on one side of the head that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- ATO-TOPIRAMATE (NCT05748483)
- Testing
- Atogepant, Topiramate
- Where
- 81 sites in Austria, Belgium and 10 more
- Volunteers
- 545 people
- Sponsor
- AbbVie
Chronic Migraine
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
- Trial name
- REGAIN (NCT02614261)
- Testing
- Galcanezumab
- Where
- 117 sites in United States, Argentina and 11 more
- Volunteers
- 1,117 people
- Sponsor
- Eli Lilly and Company
Migraine
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could…
- Trial name
- HER-MES (NCT03828539)
- Testing
- Erenumab, Topiramate
- Where
- 79 sites in Germany
- Volunteers
- 777 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Migraine
Study to Evaluate the Efficacy of Intranasal Kinetic Oscillation Stimulation in the Preventive Treatment of Chronic Migraine
The efficacy of intranasal kinetic oscillation stimulation using the Chordate System S211 as a preventative treatment will be examined in patients diagnosed with chronic migraine.
- Trial name
- NCT03400059
- Testing
- Chordate System S211 in treatment mode
- Where
- 10 sites in Finland, Germany
- Volunteers
- 144 people
- Sponsor
- Chordate Medical
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 [monthly TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3 months] compared with placebo for preventive…
- Trial name
- NCT03303079
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 571 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Chronic Migraine
Efficacy and Safety of Nerivio Device for Acute Treatment of Migraine in People With Chronic Migraine
A prospective, single arm, open-label, multicenter trial to assess the efficacy and safety of the Nerivio device in chronic migraine patients.
- Trial name
- NCT04194008
- Testing
- Nerivio
- Where
- 10 sites in United States
- Volunteers
- 126 people
- Sponsor
- Theranica